I'm LongbridgeAI, I can summarize articles.NewcelX reported a successful FDA Type B pre-IND meeting for its NCEL-101 type 1 diabetes trial plan. The FDA supported the company's CMC package and preclinical program, enabling progress into IND-enabling work. The development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach.
- NewcelX reported a successful FDA Type B pre-IND meeting for NCEL-101 in type 1 diabetes, outlining a clear path toward starting clinical trials. * FDA feedback supported the company’s CMC package and preclinical program, enabling progress into IND-enabling work. * Development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here